PARP inhibitors as first-line maintenance therapy in ovarian cancer: Update from SGO 2022

touchCONGRESS for touchONCOLOGY

Listen to Prof. Isabelle Ray-Coquard (France) cover key data presented at SGO 2022 on PARP inhibitors as first-line maintenance therapy in ovarian cancer, and their implications for clinical practice, including expert insights and interpretation from Dr Antonio González-Martín (Spain) and Dr Sandro Pignata (Italy).

OVERVIEW

• Data review with Prof. Ray-Coquard (0:32)
• Expert interviews with Dr González-Martín, Dr Pignata and
  Prof. Ray-Coquard, answering the questions below

INTERVIEW QUESTIONS

1. 1. How have the clinical trial data regarding first-line maintenance with PARP inhibitors in patients with ovarian cancer changed our understanding of the efficacy of these treatments? (22:56)
   2. What have we learned about managing adverse events in patients with ovarian cancer receiving first-line maintenance with PARP inhibitors? (29:21)
   3. Based on the presentations at SGO 2022, are you likely to change how you personalize treatment by considering the patient’s molecular characteristics? (36:32)
   4. What can we learn from the real-world evidence for first-line maintenance with PARP inhibitors presented at SGO 2022? (43:15)
   5. How do you see the role and optimization of PARP inhibitors in the first-line maintenance treatment of advanced ovarian cancer evolving in the next 5 years? (49:39)

This touchPODCAST is for HCPs only. 

This activity is funded by an unrestricted independent medical education grant from GlaxoSmithKline. This activity is provided by touchIME.

For further information visit our website: https://touchoncology.com/education/parp-inhibitors-maintenance-sgo2022/